<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04023526</url>
  </required_header>
  <id_info>
    <org_study_id>CR108609</org_study_id>
    <secondary_id>2019-000473-23</secondary_id>
    <secondary_id>74494550AML2001</secondary_id>
    <nct_id>NCT04023526</nct_id>
  </id_info>
  <brief_title>A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy</brief_title>
  <acronym>CULMINATE</acronym>
  <official_title>A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>argenx BVBA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of cusatuzumab in combination with
      azacitidine in participants with previously untreated acute myeloid leukemia (AML) who are
      not eligible for intensive chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AML is a heterogeneous disease characterized by uncontrolled clonal expansion of
      hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for
      the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts
      harvested from newly diagnosed AML participants expressed Cluster of Differentiation (CD) 70
      on the cell surface. Cusatuzumab (JNJâ€‘74494550) is a humanized monoclonal antibody of camelid
      origin, binding with tight affinity to human CD70. Cusatuzumab has been modified to induce
      enhanced antibodydependent cell-mediated cytotoxicity for therapeutic use in participants
      with cancer. Azacitidine is a pyrimidine nucleoside analogue of cytidine with antineoplastic
      activity and is indicated for the treatment of adult participants with AML or intermediate 2
      and high-risk myelodysplastic syndrome (MDS) with greater than 20% marrow blasts who are not
      eligible for hematopoietic stem cell transplantation. This study will evaluate 2 doses of
      cusatuzumab in combination with standard dose azacitidine in participants with AML who are
      not candidates for intensive chemotherapy (Part 1). Part 1 data will be reviewed by a Data
      Review Committee to select a preferred dose of cusatuzumab. Participants will be enrolled
      into Part 2 at the selected cusatuzumab dose to further evaluate and confirm the response
      rate, other efficacy endpoints, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD).
      The study will include a Screening Phase (28 days prior to randomization), a Treatment Phase,
      and a Follow-up Phase. The study includes evaluations like vital signs, electrocardiogram,
      spirometry test, serum chemistry and hematology tests. The study will be conducted for an
      approximate duration of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Response (CR)</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR with Partial Hematological Recovery (CRh)</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR plus CRh</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR with Incomplete Recovery (CRi)</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with CR without MRD</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level &lt;10^-3; determined by central lab).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS)</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as less than (&lt;) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level &lt;10^-3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Time to response is defined as time from randomization in Part 1 or enrollment in Part 2 to achieving the first response of CR, CRh, or CRi.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 1.4 years</time_frame>
    <description>Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to disease relapse or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) or Platelets Transfusion Independence</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Transfusion independence (RBC or platelets) is defined as a period of at least 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 1.9 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Cusatuzumab</measure>
    <time_frame>Up to 1.9 years</time_frame>
    <description>Cmin is the minimum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Cusatuzumab</measure>
    <time_frame>Up to 1.9 years</time_frame>
    <description>Cmax is the maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-cusatuzumab Antibodies</measure>
    <time_frame>Up to 1.9 years</time_frame>
    <description>Number of participants exhibiting anti-drug antibodies for cusatuzumab alone and in combination with azacitidine will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee (DRC) and when a dose of cusatuzumab is selected, randomization will stop and participants will be enrolled into an expansion cohort (Part 2) to evaluate efficacy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a DRC and when a dose of cusatuzumab is selected, randomization will stop and participants will be enrolled into an expansion cohort (Part 2) to evaluate efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle.</description>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cusatuzumab</intervention_name>
    <description>Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg.</description>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg</arm_group_label>
    <arm_group_label>Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg</arm_group_label>
    <other_name>JNJ-74494550</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia (AML) according to World Health Organisation (WHO) 2016
             criteria and fulfilling all of the following criteria that defines those who are &quot;not
             candidates for intensive chemotherapy&quot;:

               1. greater than or equal to (&gt;=)75 years of age or

               2. less than (&lt;) 75 years of age with at least one of the following comorbidities:
                  Eastern Cooperative Oncology Group (ECOG) Performance Status of 2; Severe cardiac
                  comorbidity defined as congestive heart failure or ejection fraction less than or
                  equal to (&lt;=) 50 percent (%); Severe pulmonary comorbidity defined as documented
                  pulmonary disease with lung diffusing capacity for carbon monoxide (DLCO) &lt;=65%
                  of expected, or forced expiratory volume in 1 second (FEV1) &lt;=65% of expected or
                  dyspnea at rest requiring oxygen; Moderate hepatic impairment defined according
                  to NCI organ dysfunction classification criteria (total bilirubin &gt;=1.5 up to 3
                  times upper limit of normal [ULN]); Creatinine clearance &lt;45 milliliter per
                  minute per 1.73 meter square (mL/ min/1.73 m^2); Comorbidity that, in the
                  Investigator's opinion, makes the participant unsuitable for intensive
                  chemotherapy and must be documented and approved by the Sponsor before
                  randomization

          -  De novo or secondary AML

          -  Previously untreated AML (except: emergency leukapheresis, hydroxyurea, and/or 1 dose
             of cytarabine [example: 1-2 gram per meter square {g/m^2}] during the Screening Phase
             to control hyperleukocytosis. These treatments must be discontinued &gt;=24 hours prior
             to start of study drug). Empiric all trans retinoic acid (ATRA) treatment for presumed
             acute promyelocytic leukemia (APL) is permitted but APL must be ruled out and ATRA
             must be discontinued &gt;=24 hours prior to the start of study drug

          -  Not eligible for an allogeneic hematopoietic stem cell transplantation

          -  ECOG Performance Status score of 0, 1 or 2

        Exclusion Criteria:

          -  Acute promyelocytic leukemia

          -  Leukemic involvement or clinical symptoms of leukemic involvement of the central
             nervous system

          -  Use of immune suppressive agents for the past 4 weeks before the first administration
             of cusatuzumab on Cycle 1 Day 3. For regular use of systemic corticosteroids,
             participants may only be included if free of systemic corticosteroids for a minimum of
             5 days before the first administration of cusatuzumab. Treatment of adrenal
             insufficiency with physiologic replacement doses of corticosteroids are allowed

          -  Prior treatment with a hypomethylating agent for treatment of AML or myelodysplastic
             syndrome (MDS)

          -  Active malignancies (that is, progressing or requiring treatment in the last 24
             months) other than the disease being treated under the study

          -  Any active systemic infection

          -  Known allergies, hypersensitivity, or intolerance to cusatuzumab or azacitidine or its
             excipients (that is, mannitol, an excipient of azacitidine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincents Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Do Cancer De Barretos - Fundacao Pio Xii</name>
      <address>
        <city>Barretos</city>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual de Campinas - Centro de Hematologia e Hemoterapia</name>
      <address>
        <city>Campinas</city>
        <zip>13083-878</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de ClÃ­nicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nossa Senhora da Conceicao</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Instituto do Cancer do Estado de Sao Paulo 'Octavio Frias de Oliveira' - ICESP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille Cedex 9</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre - BÃ©nite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU Tours HÃ´pital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3436212</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Division of Hematology, Cardarelli Hospital</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata di Udine</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chelyabinck Regional Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ekaterinburg City Clinical Hospital # 7</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>S.P. Botkin Moscow City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital # 40</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod Regional Oncology Dispensary</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ryazan Regional Clinical Hospital</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City clinical hospital #15</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samara Region Clinical Hospital</name>
      <address>
        <city>Samara</city>
        <zip>443095</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologic Dispensary No.2</name>
      <address>
        <city>Sochi</city>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.-Petersburg Clinical Research Institute of Hematology and Transfusiology</name>
      <address>
        <city>St. Petersburg</city>
        <zip>193024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Komi Republic Oncology dispensary</name>
      <address>
        <city>Syktyvkar</city>
        <zip>167904</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inst. Cat. Doncologia-H Duran I Reynals</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Son Espases</name>
      <address>
        <city>Palma</city>
        <zip>7120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Quiron Madrid Pozuelo</name>
      <address>
        <city>Pozuelo De Alarcon, Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. I Politecni La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>INSELSPITAL, UniversitÃ¤tsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gulhane Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Hematology Department - Hematology</name>
      <address>
        <city>Ankara</city>
        <zip>6100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ondokuz Mayis Universitesi Tip Fakultesi</name>
      <address>
        <city>Atakum</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istanbul Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Universitesi Tip Fakultesi</name>
      <address>
        <city>Ä°zmir</city>
        <zip>35210</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik University Medical Faculty</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108609</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2019</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

